Steven A. Matthes

  • Citations Per Year
Learn More
Cyclophosphamide, cisplatin, and carmustine (CPA/cDDP/BCNU) constitute a combination alkylating-agent regimen commonly used with autologous marrow support. Its therapeutic effectiveness is accompanied by sporadic life-threatening and fatal toxicities, the most common of which is acute lung injury. We have previously shown that variation in the BCNU AUC can(More)
Interpatient variability in exposure to certain chemotherapy agents can influence patient outcome, particularly with high-dose chemotherapy. We evaluated the possibility of a pharmacokinetic (PK) drug–drug interaction between the antiemetic agents and high- dose cyclophosphamide, cisplatin and BCNU (CPA/cDDP/BCNU). Twenty-three self-selected patients(More)
Combinations of alkylating agents in intensive doses with autologous hematopoietic cell support (AHCS) are commonly used to treat advanced, solid tumors. Relatively little is known about the pharmacokinetic or pharmacodynamic aspects of their use. The cyclophosphamide, cisplatin, and BCNU (CPA/cDDP/BCNU) regimen is often used in patients with breast cancer.(More)
The Severe Environment Corrosion and Erosion Research Facility (SECERF) at the Albany Research Center is operational. SECERF consists of 6 modules that share the availability of up to 10 different gases to produce environments for high temperature corrosion and erosion research. Projects to be conducted in the modules include: corrosion sensors for fossil(More)
We conducted a randomized, double blind, placebo-controlled multi-institutional trial to assess the ability of amifostine to protect patients against acute lung injury associated with cyclophosphamide/cisplatin/carmustine (BCNU) (STAMP I), a BCNU-containing high dose chemotherapy regimen used with hematopoietic cell transplantation. Amifostine was(More)
from the treatment. For several years we have been evaluating the role of radiolabeled antibodies that react with cell surface milk fat globule antigens in the imaging and treatment of patients with lung and breast cancers. †̃311-labeledBrE-3 therapy was tested in an immunodeficient mouse model grafted with MX-! tumor that has an intermediate to low(More)
  • 1